{"name":"BeyondSpring Pharmaceuticals Inc.","slug":"beyondspring-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Docetaxel (D)","genericName":"Docetaxel (D)","slug":"docetaxel-d","indication":"Metastatic breast cancer","status":"marketed"},{"name":"Docetaxel + Plinabulin (DP)","genericName":"Docetaxel + Plinabulin (DP)","slug":"docetaxel-plinabulin-dp","indication":"Metastatic non-small cell lung cancer (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"Docetaxel (D)","genericName":"Docetaxel (D)","slug":"docetaxel-d","phase":"marketed","mechanism":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Prostate cancer","Gastric adenocarcinoma","Head and neck cancer"],"catalyst":""},{"name":"Docetaxel + Plinabulin (DP)","genericName":"Docetaxel + Plinabulin (DP)","slug":"docetaxel-plinabulin-dp","phase":"phase_3","mechanism":"Docetaxel inhibits microtubule depolymerization to arrest cell division, while plinabulin disrupts microtubule dynamics and suppresses neutrophil migration to enhance chemotherapy efficacy and reduce chemotherapy-induced neutropenia.","indications":["Metastatic non-small cell lung cancer (Phase 3)","Advanced solid tumors (investigational)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOVXRlTmJtbHlic0h3QmpwdWVuU1otU0dnY1JPVHg3MENuM3doSW1Lblp5enNLcUV2MGdaM0VHc2ZpeTdoUms5SGRlYUF5cUhPOXo2c0JybW11a1JNMVlBcnFUdkdDc0ppWGltTWN1a1ZyZTR2c3ZhbHB2NnluU1VGZXR6cG9YNU9pUTdmM2RJMjV1aFBPMlF0MmpJY3ZlejJsSTU0ZGRQMGRDQWRNaWlvTFVWT1QwTHJNeFVkMTRqYzVtWUxSYUNUTXRmTlExN015Z2F5NkFCWUNIcDhZQ2NYc0IwUTk5NzE0dC10WkY1X1dyOHZKX1BYRVdkSHF4QTJYZUVleVBOSjR2MTZpZWlOdFNzeEF2a3hnWnBxVzFlRllQT2JGdkVqM2JWZEJXQ1V1QlRKY0h4SGVORndjZjlzZWNmUnE0dlFHSmRJTnZmSV9odUJkSW04?oc=5","date":"2025-01-28","type":"pipeline","source":"GlobeNewswire","summary":"BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire","headline":"BeyondSpring Announces $35.4 Million Sale of a Portion of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxObDVIWVNwRnJyeDlHUEptTzdZd0FtaEs5bzY2ZHZ6Qm9wRGlCelVzbjlFRVVubzBTQnBoVmJvR1k1TFkzMU9kSHowc2w5SGcxNmNmb1c5ZFp5ZVkxN1EyaXZrdktVNWZEWXNoLUVWQm9WRC1veDh5Vk5tWlJyT1FNUXpaYXp2b0RaSWxpMHl5Z0hua0hLM2VGb2dEMGxybEZNOEl5OW44emo3aGZoQzJ3eWpiYkNqcER3alpMazdFbWxOanNISWFMT2EtaFFwOG9NY00zWHo3dDlvUFM4WXUxNQ?oc=5","date":"2024-08-22","type":"pipeline","source":"prnewswire.com","summary":"Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - prnewswire.com","headline":"Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPVWlWbzZNNThXTXRxRlFjMFJ5cDNQQ1Ftay1FT21iTEQ4MzlPakZZRmZpVXFPLWg2UXdUa2pGdzVGeDBNLXFDTUVib0NNVEEtWG9IaFdlUXBJc0lOMFFzQUVwOUlEZUlxZEkyLXNpWEdIdGNaN2lYSFhTeTU2N1lTTENXRk5UdFdGbmRTRE1jTEtZbHdrOFJwdnRMbGhrZkJJd0djcUtn?oc=5","date":"2024-08-09","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—The TROP2 ADC race; Another Merck-Daiichi cancer deal; Eisai's molecular glue pact - Fierce Pharma","headline":"Fierce Pharma Asia—The TROP2 ADC race; Another Merck-Daiichi cancer deal; Eisai's molecular glue pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOZjYwbklrS0dFNERFOXV2eW1rRXlZWkRkU1hRREZLZDUzeUZORExqTnpaRmJXYi1aclE2OVFLRVZRSVQ1SVRlX2hWaVZQUlhRcEsySFdVV0J0akFpQXJFQXY4ZExWaDNhbmI0b0FLUEExSGZEcXpmaE9ZUFhnd3p6QWRhcGNpVHhmZ0U3aGVWcDN2V0tia09jNVdQX3VQUDJncWpEd0NBcnRoVWxmWldFcUdyVG9jMW9lMXdHVXMyQ1laUzVKN0RncDlMUlhRSFJqOC0xYlpDM3k0YWNNQTdzTjl1SldDQ1V3ZGtrQlY5b1k5Ym9icWprbDdaYkkxU1BHUzR0V1g4VTNzRW05REdWamJsVnowMmJzaU9nMkMwU2pjSVNP?oc=5","date":"2024-07-11","type":"trial","source":"prnewswire.com","summary":"Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQWUoxZzBKRFFjR3hfeDRfMDBwMUoyV1JrOXZSVEhXSEtpazdJSXQzcU92LVp6MGZTZXFjZUxNbnpkbTRPcTVrTU1aMXZES3FUbk4tb3c4OVEyT3I0MHRXUFQtX1dNQy02UXBPMDN0VzNTUlB1QW5fbjlxX3h3NXVJT3Y0WS1sSGdL?oc=5","date":"2024-05-04","type":"pipeline","source":"OpenSecrets","summary":"Pharmaceuticals/Health Products Lobbying Profile - OpenSecrets","headline":"Pharmaceuticals/Health Products Lobbying Profile","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQYTVJamM3cU42TWQtZTFtZGNkOHdDc21pOXR0b3cwVHVLMmhscUg2RC1wOG5adWxYd0ZrNTk5bGQzWkJWaFRVZEpWUFV2ZUZnY1FIN2xzU2dHYnhCUlYyZ2xULUoxWWh6aUFrOEFucm9BbjdfYjVWR1NFZi1rd3ZxNmtsNkNXd2w3MTBpY3NWX2NYZnRwQVp1d0ZjZDRIVTd2MzZWWWFBT0oxQWdsbml4WTNxWUdLcDBCOF95Y2xTZm1aVEFUemdFNldudERCbVhXa1F4ckVNUWJHWFB4YlN6NkNWNW95OHVNVlVhYWN4VWk2cXRrQW9iN0xn?oc=5","date":"2023-10-10","type":"trial","source":"ascopost.com","summary":"Extended Follow-up of TROPiCS-02 Trial Sacituzumab Govitecan in Metastatic Breast Cancer - ascopost.com","headline":"Extended Follow-up of TROPiCS-02 Trial Sacituzumab Govitecan in Metastatic Breast Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOT1Ixal9QV2FGMDYwM29TZTJaN3loMzd3eWQwelVJN1k0RFBrdHU5RVNzLXdlRUFCbTFEbk5UZW54azU4N0JCNnNDMUdLcTN1N004MHI1VDFjSUxMWnJaS09rd0ZVTXI2RDRONEM0MW5Wa292V2RocHplejkzUFRSVHRLX2RRXzVUNEg1cw?oc=5","date":"2022-12-13","type":"pipeline","source":"Yahoo Finance","summary":"Why Are BeyondSpring Shares Trading Higher? - Yahoo Finance","headline":"Why Are BeyondSpring Shares Trading Higher?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcko5ZnRoZFZ1c2YyZ20wM0xHMXJOM1R0ZlZBVVJMYW5yMDlHaWZpMUNmLXFXT1JoWExXNUF5VnJRUm50UzJYZ2J0ZzlPUFFlbGpuRURlVXB0eVFkUkF1clZYYVNRaDdmOEl6dEdjSEFKbmtkODFaNE1xZXFNWmtQdU81M01yYXBtblRBR0FZU2kwa0ItZE9DYTBta1VnTUJCWVB6SzFaUFE3OUE?oc=5","date":"2021-12-01","type":"regulatory","source":"MedCity News","summary":"FDA turns down BeyondSpring chemo complication drug, asks for another trial - MedCity News","headline":"FDA turns down BeyondSpring chemo complication drug, asks for another trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQV25QN1ZSVS1LN0lMZVdBYnBuaDdnYXFMSkJOQjdDaWl0OE0wZEc2eUJRd040aUVhSHBLNi1RdlRmZFBZSnJacHE0RDltcXViQ1R0NWV1Rmxrc1IwVlJ0eTRDdFFnWWh5YjhCMmFfVm5xS0hlekttUEt5SUNFM3p0YVZtQlBWX2dETkNYbXZrQ3hZUWFKVElnM0pPQ25xYjV0aTB4Rg?oc=5","date":"2021-07-14","type":"pipeline","source":"citybiz","summary":"BeyondSpring Appoints Brendan Delaney to its Board of Directors - citybiz","headline":"BeyondSpring Appoints Brendan Delaney to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNanJPdFVZaVZtWWJLYzd1c1ZxRjJHbXZFZEJIVGdQdVZ1MWxXRTFjSGdsWnFNaXc5SXRiQ2xOQUkyMjRmUWpkRm84a09nU2t6YVljNkFKeU9SQkVHckEyU3ZWdXBXQXpuSXc0aTlydXZ6U09rdUQxYkNRN2dtU2NKMDZVcDM1ZjRFNjBr?oc=5","date":"2020-11-13","type":"pipeline","source":"BioPharma Dive","summary":"Lilly backs a biotech’s spinout and places a small bet on protein degradation - BioPharma Dive","headline":"Lilly backs a biotech’s spinout and places a small bet on protein degradation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNbGdlNDR4ZnQ4bFN3akpQUkFPdVdzRG1kdGVUUnJQSEdSLXZ6OVpLTkNoOVlteFQyVkJuMDBEeGpETnFaNFFCMHg4b29FUnkycmEtVTdqSmdVZXZKN2p1dmtDNkdRQUpKSjdndUsxNGItUUNGSktMRlliY0lBSU1JSmJnZ2ZTekxOeXI0bkJvMEQ2cE1hY0JGUFRQMkhMS3N5TjZXYllfX2tsVTF0WUtvQkE2WHdZeXJreEtzamZ1MmV4d0FkWVB4ZUFpTnRUQ0wyb1J1dFkzVXc0NjBiTzVIRERWcGdHUzFTODdORHpPUmFBTE9nQ2otLTJJeUt1SzZaNllPRzNaeE11UWc?oc=5","date":"2020-11-13","type":"deal","source":"GlobeNewswire","summary":"BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly - GlobeNewswire","headline":"BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9DT1htcms4WTdPeVF0NU80VC1KU1ljUzYxbmZmMEJrNEtGYWk2ZVpOVlNOXzJRY2diNEY0NWE0OThKMk90TlI3bmxiemFDQmZrb1VSX19uQ0dzTktaMlJWQXdZV0JaR0g2TTB2NU9pS203M0xSdjFNek01N1hrQQ?oc=5","date":"2017-03-09","type":"pipeline","source":"pharmaphorum","summary":"Cancer biotech BeyondSpring hit by weak IPO - pharmaphorum","headline":"Cancer biotech BeyondSpring hit by weak IPO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}